1. ICH Harmonized Tripartite Guideline Q5A 1999(R1): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin
2. EMEA/CHMP/BWP/398498, 2009: Guideline on virus safety evaluation of biotechnological investigational medicinal products
3. USP 1st Supplement 40-NF35 <1050.1>: Design, Evaluation, and Characterization of Viral Clearance Procedures (2017)
4. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding;Lu;Lancet,2020
5. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Review;Adamson;Dev Biol Stand,1998